Evidence map›Paper›PMID 38627249›Full record

ArticleBioinformatics (Oxford, England)2024

AbLEF: antibody language ensemble fusion for thermodynamically empowered property predictions.

Zachary A Rollins, Talal Widatalla, Andrew Waight, Alan C Cheng, Essam Metwally

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zachary A RollinsModeling and Informatics, Merck & Co., Inc, South San Francisco, CA, 94080, United States.ORCID 0000-0002-1087-5164
Talal WidatallaModeling and Informatics, Merck & Co., Inc, South San Francisco, CA, 94080, United States.
Andrew WaightDiscovery Biologics, Merck & Co., Inc, South San Francisco, CA, 94080, United States.
Alan C ChengModeling and Informatics, Merck & Co., Inc, South San Francisco, CA, 94080, United States.ORCID 0000-0003-3645-172X
Essam MetwallyModeling and Informatics, Merck & Co., Inc, South San Francisco, CA, 94080, United States.

Funding

Merck & Co., Inc
6 · The paper itself

Abstract

motivationPre-trained protein language and/or structural models are often fine-tuned on drug development properties (i.e. developability properties) to accelerate drug discovery initiatives. However, these models generally rely on a single structural conformation and/or a single sequence as a molecular representation. We present a physics-based model, whereby 3D conformational ensemble representations are fused by a transformer-based architecture and concatenated to a language representation to predict antibody protein properties. Antibody language ensemble fusion enables the direct infusion of thermodynamic information into latent space and this enhances property prediction by explicitly infusing dynamic molecular behavior that occurs during experimental measurement.

resultsWe showcase the antibody language ensemble fusion model on two developability properties: hydrophobic interaction chromatography retention time and temperature of aggregation (Tagg). We find that (i) 3D conformational ensembles that are generated from molecular simulation can further improve antibody property prediction for small datasets, (ii) the performance benefit from 3D conformational ensembles matches shallow machine learning methods in the small data regime, and (iii) fine-tuned large protein language models can match smaller antibody-specific language models at predicting antibody properties. AVAILABILITY AND IMPLEMENTATION: AbLEF codebase is available at https://github.com/merck/AbLEF.

Indexed as

ThermodynamicsAntibodiesComputational BiologyHydrophobic and Hydrophilic InteractionsMachine LearningProtein ConformationSoftwareAntibodies

Identifiers

PMID38627249
PMCPMC11256947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.